Dyngo® 4a, Novel, highly potent dynamin inhibitor (ab120689)
Key features and details
- Novel, highly potent dynamin inhibitor. Dynasore (ab120192) analog.
- CAS Number: 1256493-34-1
Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Dyngo® 4a, Novel, highly potent dynamin inhibitor -
Description
Novel, highly potent dynamin inhibitor. Dynasore (ab120192) analog. -
Biological description
Novel, highly potent dynamin inhibitor (IC50 values are 400 nM and 200 nM at dynamin I and II human-recombinant, respectively). Inhibits clathrin-mediated endocytosis (IC50 = 5.5 µM). Dynasore (ab120192) analog. Prevents botulin neurotoxin A (BoNTs) uptake and internalization, and prevents SNAP25 cleavage. Inhibits BoNTs induced paralysis and delays botulism onset.
-
General notes
Sold under exclusive licence from Children's Medical Research Institute and Newcastle Innovation Ltd. Dyngo® is a trademark of Children's Medical Research Institute and Newcastle Innovation Ltd.
-
CAS Number
1256493-34-1 -
Chemical structure
Properties
-
Chemical name
3-Hydroxy-N'-[(2,4,5-trihydroxyphenyl)methylidene]naphthalene-2-carbohydrazide
-
Molecular weight
338.31 -
Molecular formula
C18H14N2O5 -
PubChem identifier
136227923 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM
-
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
C1=CC=C2C=C(C(=CC2=C1)C(=O)N/N=C/C3=CC(=C(C=C3O)O)O)O -
Source
Synthetic
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120689 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Images
-
Chemical Structure - Dyngo® 4a, Novel, highly potent dynamin inhibitor (ab120689)2D chemical structure image of ab120689, Dyngo® 4a, Novel, highly potentdynamin inhibitor
-
Functional Studies - Dyngo® 4a, Novel, highly potent dynamin inhibitor (ab120689)Kockx M et al. PLoS One. 2014; 9(10): e111186. doi: 10.1371/journal.pone.0111186 Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/Primary human monocyte-derived macrophages were treated without (Ctrl) and with ab120689 (Dyngo 4A) for 2 h. Effects on α-tubulin and acetylated tubulin (Ac-tubulin) were determined by confocal microscopy.
Credit: Kockx M et al. PLoS One. 2014; 9(10): e111186. doi: 10.1371/journal.pone.0111186
-
Immunocytochemistry/ Immunofluorescence - Dyngo® 4a, Novel, highly potent dynamin inhibitor (ab120689)ab66705 staining PAI1 in HeLa cells treated with dyngo-4a™(ab120689), by ICC/IF. Increase in PAI1 expression correlates with increased concentration of dyngo-4a™, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab120689 (dyngo-4a™) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab66705 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (66)
ab120689 has been referenced in 66 publications.
- Polanco JC et al. CRISPRi screening reveals regulators of tau pathology shared between exosomal and vesicle-free tau. Life Sci Alliance 6:N/A (2023). PubMed: 36316035
- Jobin ML et al. Filamin A organizes γ‑aminobutyric acid type B receptors at the plasma membrane. Nat Commun 14:34 (2023). PubMed: 36596803
- Cappelli J et al. Glycine-induced NMDA receptor internalization provides neuroprotection and preserves vasculature following ischemic stroke. iScience 25:103539 (2022). PubMed: 34977503
- Maja M et al. Surface cholesterol-enriched domains specifically promote invasion of breast cancer cell lines by controlling invadopodia and extracellular matrix degradation. Cell Mol Life Sci 79:417 (2022). PubMed: 35819726
- Cardoso DA et al. High-Content Drug Discovery Screening of Endocytosis Pathways. Methods Mol Biol 2233:71-91 (2021). PubMed: 33222128